Last reviewed · How we verify

Pre-Quit Nicotine Gum

University of Wisconsin, Madison · FDA-approved active Small molecule

Pre-Quit Nicotine Gum delivers nicotine orally to reduce withdrawal symptoms and cravings during smoking cessation.

Pre-Quit Nicotine Gum delivers nicotine orally to reduce withdrawal symptoms and cravings during smoking cessation. Used for Smoking cessation aid.

At a glance

Generic namePre-Quit Nicotine Gum
SponsorUniversity of Wisconsin, Madison
Drug classNicotine replacement therapy
TargetNicotinic acetylcholine receptors
ModalitySmall molecule
Therapeutic areaSmoking Cessation / Addiction Medicine
PhaseFDA-approved

Mechanism of action

The gum formulation allows for controlled, gradual release of nicotine that is absorbed through the oral mucosa, providing a substitute source of nicotine independent of cigarettes. This reduces the severity of withdrawal symptoms (irritability, anxiety, difficulty concentrating) and cravings that typically occur when smokers attempt to quit. By maintaining some nicotine exposure while eliminating the harmful combustion products of cigarettes, it facilitates the behavioral transition away from smoking.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: